Signal-targeted therapies in cancer & resistance


Since over 20 years, novel therapies targeting intra- and extra-cellular signaling are developed.These therapies annihilate major oncogenic pathways, that drive tumorigenesis in each cancer sub-types. The most recent & spectacular example is represented by a mutated B-Raf inhibitor (Vemurafenib) with which, under treatment, partial and complete remissions were observed in metastatic melanoma patients. Compounds inhibiting PI3K signalling pathway are also under clinical trials, with a compound targeting PI3Kδ GS-1101 (Idelalisib/CAL-101) in immune compartment, being the first PI3K inhibitor to be approved for clinical use. These therapies, however, rapidly induce resistance.

These responses to treatment come from cancer and metastatic cells themselves, but also from the tumor in its microenvironment. Understanding molecular mechanisms underpinning interconnection of oncogenic cellular signalling and cellular metabolism or genomic instability, as well as understanding common signalling pathways in immune, cancer and vascular cells will help us to predict resistance to these signal-targeted therapies and to imagine the future anti-cancer treatments.


23rd of November 2017, 9.05am-4.30pm


Conferences will be held at Pierre Fabre's Center for Research and Development, 3 avenue Hubert Curien, 31100 Toulouse

Lunch and poster session will be held at the Cancer Research Center of Toulouse, 2 avenue Hubert Curien, 31100 Toulouse

Please note that ID is compulsory to enter the premises.

Please also note that the nearest available car park is IUCT-O's.


9h05-9h30         Welcome of participants (Pierre Fabre's Center for Research & Development)

9h30-9h35         Introduction Directors - Christian FILAQUIER (Pierre Fabre's Center for R&D) & Gilles FAVRE (Cancer Research Center of Toulouse)

9h35-10h20       Plenary conference 1 - Pr. Arkaitz CARRACEDO (CIC bioGUNE, Bilbao, Spain): mTOR signalling & metabolism

10h20-11h05     Plenary conference 2 - Dr. Ezra AKSOY (William Harvey Institute, London, UK) (conference organised by the Fondation Toulouse Cancer Santé): p110delta PI3K regulates gut immunity and inflammation by unconventional autophagy

11h05-11h25     Short talk 1

11h25-11h55     Coffee break

11h55-12h15     Short talk 2

12h15- 13h00    Plenary conference 3 - Dr. Celine GONGORA (Institute for Research on Cancer of Montpellier, France): Synthetic lethality screening identify ATR to synergize with oxaliplatin treatment in colorectal cancer

13h00- 13h15    >>> Go to CRCT

13h15-14h30     Lunch & Poster session (Cancer Research Center of Toulouse, meeting-room Christophe Cazaux)

14h30-14h45     >>> Go to Institut de Recherche Pierre Fabre

14h45-15h05     Short talk 3

15h05-15h25     Short talk 4

15h25-16h10     Plenary conference 4 - Pr. Emilio HIRSCH (University of Torino, Italy): Loss of PI3K-C2alpha in breast cancer leads to genomic instability but increases Taxane sensitivity

16h10-16h20     Conclusions & take-home messages - Julie GUILLERMET-GUIBERT (promotor of the symposium, team leader at CRCT)



For registration and abstract/poster submission, please login (above this page, on the right)

Attention: the number of participants is limited at 100

This symposium is kindly hosted by Pierre Fabre's Center for Research and Development and jointly organized by the Cancer Research Center of Toulouse, the SFR-BMT and the Fondation Toulouse Cancer Santé. The symposium benefits from the institutional support of Pierre Fabre Laboratories, Gilead Sciences, Cancéropôle GSO and the Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN).


Online user: 1